Immune Modulating Effects of Poly(ICLC) in Mice, Monkeys and Man

  • Hilton B. Levy
  • Christopher BeverJr.
Part of the Polymer Science and Technology book series (PST, volume 38)


The stabilized double stranded RNA, poly(ICLC), in addition to being an active interferon inducer, is able to modify a variety of humoral and cell associated immune activities in mice, monkeys and humans. In mice there is augmentation, in vitro and in vivo of macrophage activation and NK cell activity, as well as specific cytotoxic T cells. In primates, poly(ICLC) increases the amount and rapidity of formation of antibodies to a number of weak vaccines. In addition there is increased macrophage and 2′5′ A. synthetase activities. At low doses there is an augmentation of NK cell action, but inhibition at higher doses. Increases in T4/T8 ratio were found. Lymphocyte subset populations are modified in different ways, depending on the dose. In general low doses augment the several immune actions much better than do the higher doses.


Natural Killer Cell Activity Mixed Lymphocyte Reaction Rift Valley Fever Rift Valley Fever Virus Venezuelan Equine Encephalitis Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    H. B. Levy, F. L. Riley in: “Polymers in Medicine”, E. Chiellini & P. Giusti, Eds., Plenum Pub. Co., New York, 1983, pp. 33–35,CrossRefGoogle Scholar
  2. 2.
    E. L. Stephen, D. E. Hilmas, J. A. Marigrafico & H. B. Levy, Science, 197, 1289–1290 (1977).CrossRefGoogle Scholar
  3. 3.
    H. B. Levy, J. Bioactive and Compatible Polymers, 1, 348–385 (1986).CrossRefGoogle Scholar
  4. 4.
    D. L. Harrington, C. L. Crabbs, D. E. Hilmas, J. R. Brown, C. A. Higbee, F. E. Cole & H. B. Levy, Infect. Immun., 24, 160–166 (1979).Google Scholar
  5. 5.
    M. A. Chirigos, V. Papademetriou, A. Bartocci, E. Read, & H. B. Levy, Int. J. Immunpharmac. 3, 329–337 (1981).CrossRefGoogle Scholar
  6. 6.
    J. A. Talmadge, J. Adams, H. Philips, M. Collins, B. Lenz, M. Snyder, & M. Chirigos, Cancer Research, 45, 1058–1065 (1985).Google Scholar
  7. 7.
    J. E. Talmadge & D. Hartmann, J. Biol. Resp. Mod., 4, 484–489 (1985).Google Scholar
  8. 8.
    E. DeMaeyer & J. DeMaeyer-Guignard, Ann. N.Y. Acad. Sci., 350, 1–11 (1980).CrossRefGoogle Scholar
  9. 9.
    H. B. Levy & F. Riley in: “The Lymphokines”, E. Pick, ed., Academic Press, New York, 1983.Google Scholar
  10. 10.
    C. T. Bever, Jr., H. F. MacFarland, D. E. MaFarlin, & H. B, Levy, J. Int. Res., in press.Google Scholar
  11. 11.
    A. S. Levine, M. Sivalich, P. H. Viernick, & H. B. Levy, Cancer Research, 39, 1645, 1979.Google Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • Hilton B. Levy
    • 1
  • Christopher BeverJr.
    • 2
  1. 1.National Institutes of Allergy and Infectious DiseasesBethesdaUSA
  2. 2.Department of NeurologyUniversity of Maryland HospitalBaltimoreUSA

Personalised recommendations